Latest Aromatase inhibitor Stories
Results presented at American Association of Cancer Research Annual Meeting 2015, Philadelphia, April 18-22 PHILADELPHIA, April 22, 2015 /PRNewswire/ -- Researchers at the Cancer Research
Romosozumab Currently in Phase 3 Clinical Development, Pivotal Data Expected in 2016 THOUSAND OAKS, Calif. and BRUSSELS, Sept.
Data Include Eight Year Analyses of Bone Mineral Density Results for Prolia® (Denosumab) and Further Evidence for Significant Bone-Building With Romosozumab THOUSAND OAKS, Calif., Sept.
A new study found that both real and “sham” acupuncture were able to reduce hot flashes that were a side effect of anticancer drugs called aromatase inhibitors (AI).
Researchers from the University of Alberta and Alberta Health Services have created a computer algorithm that successfully predicts whether estrogen is sending signals to cancer cells to grow into tumors in the breast.
Human epidermal growth factor (HER2) positive breast cancers are often treated with the same therapy regardless of hormone receptor status.
Researchers from Baylor College of Medicine have been awarded more than $5 million from Susan G. Komen for the Cure for three new breast cancer research grants, including a prestigious Komen Promise Grant.
- An armed gangster.